Topical immunotherapy in alopecia areata.
Singh G1, Lavanya M. Int J Trichology. 2010 Jan;2(1):36-9. doi: 10.4103/0974-7753.66911.
- 1Department of Dermatology and STD, Sri Devaraj Urs Medical College, Tamaka, Kolar – 563 101, India.
Alopecia Areata (AA) is a common non-scarring alopecia directed against the anagenic hair follicle. Various treatment modalities have been used for the treatment of severe AA. Topical immunotherapy is the best documented treatment so far for severe and refractory AA. Dinitrochlorobenzene (DNCB), squaric acid dibutylester (SADBE), and diphencyprone (DPCP) are the contact allergens used for this purpose. DNCB has been found to be mutagenic by the Ames test and is largely replaced by DPCP and SADBE. DPCP and SADBE are both known to be non-mutagenic compounds and have comparable efficacy results and relapse rates. SADBE requires special solvents and additives to maintain its potency and is more expensive than the rest. DPCP has a response rate varying from 60% in severe Alopecia Areata to 17% in patients with alopecia totalis or universalis, and shows about 88 to 100% high response rate in patients with patchy Alopecia Areata.
SADBE (squaric acid di butyl ester) alopecia Areata, dinitrochlorobenzene,